Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Pharvaris N.v. (PHVS) since 2026 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Pharvaris N.v.. Table 2 shows the detailed insider transactions. This company's CIK number is 1830487.
Total stock buying since 2026: $0.
Total stock sales since 2026: $4,621,410.
Total stock option exercises since 2026: $232,095.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 0 | $0 | 154,459 | $4,621,410 | 58,834 | $232,095 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-04 | 0 | $0 | 154,459 | $4,621,410 | 58,834 | $232,095 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 29,070 | 30.67 | 891,489 |
| 2026-04-30 | Lesage Anne (Chief Early Development) | Sale | 40,900 | 30.26 | 1,237,470 |
| 2026-04-30 | Lesage Anne (Chief Early Development) | Option Ex | 21,700 | 5.32 | 115,444 |
| 2026-04-30 | Lu Peng (Chief Medical Officer) | Sale | 15,000 | 30.24 | 453,630 |
| 2026-04-30 | Lu Peng (Chief Medical Officer) | Option Ex | 15,000 | 2.59 | 38,850 |
| 2026-04-29 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 3,830 | 30.07 | 115,164 |
| 2026-04-29 | Lesage Anne (Chief Early Development) | Sale | 7,400 | 30.07 | 222,510 |
| 2026-04-29 | Lesage Anne (Chief Early Development) | Option Ex | 3,700 | 2.59 | 9,583 |
| 2026-04-29 | Lu Peng (Chief Medical Officer) | Sale | 3,733 | 30.07 | 112,232 |
| 2026-04-29 | Lu Peng (Chief Medical Officer) | Option Ex | 3,733 | 2.59 | 9,668 |
| 2026-04-23 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 100 | 30.03 | 3,003 |
| 2026-04-23 | Lesage Anne (Chief Early Development) | Sale | 200 | 30.03 | 6,006 |
| 2026-04-23 | Lesage Anne (Chief Early Development) | Option Ex | 100 | 2.59 | 259 |
| 2026-04-23 | Lu Peng (Chief Medical Officer) | Sale | 100 | 30.03 | 3,003 |
| 2026-04-23 | Lu Peng (Chief Medical Officer) | Option Ex | 100 | 2.59 | 259 |
| 2026-04-22 | Schikan Johannes Gerardus Christiaan Petrus | Sale | 7,000 | 30.05 | 210,378 |
| 2026-04-22 | Lesage Anne (Chief Early Development) | Sale | 14,500 | 30.03 | 435,493 |
| 2026-04-22 | Lesage Anne (Chief Early Development) | Option Ex | 7,500 | 5.32 | 39,900 |
| 2026-04-22 | Lu Peng (Chief Medical Officer) | Sale | 7,001 | 30.05 | 210,401 |
| 2026-04-22 | Lu Peng (Chief Medical Officer) | Option Ex | 7,001 | 2.59 | 18,132 |
| 2026-04-16 | Modig Berndt (Chief Executive Officer) | Sale | 2,292 | 28.60 | 65,558 |
| 2026-04-09 | Modig Berndt (Chief Executive Officer) | Sale | 23,333 | 28.07 | 655,073 |
Insider trading activities including stock purchases, stock sales, and option exercises of PHVS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Pharvaris N.v. (symbol PHVS, CIK number 1830487) see the Securities and Exchange Commission (SEC) website.